Estrella Immunopharma, Inc. ESLA 深 滬
已收盤 04-02 16:00:00 美东时间
1.05
0.000
0.00%
華盛通- 最 高1.10
- 今 開1.0699
- 成交量 1.04万股
- 最 低 1.05
- 昨 收 1.05
- 總市值 4479.85万
- 52周最高 3.15
- 市盈率 靜 --
- 換手率 0.02%
- 52周最低 0.78
- 委 比 85.78%
- 總股本 4266.52万
- 歷史最高 33.00
- 量 比 0.21
- 振 幅 4.76%
- 歷史最低 0.00
- 每 手 1
- 風險率 0.45%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers SCWorx (NASDAQ:WORX) stock moved upwards by 23.3% to $0.16 during Tues...
03-11 05:06
美股大行评级 | 生化基因(BIIB)获10家大行上调目标价！Hims & Hers Health遭花旗下调目标价从30美元降至16.5美元
今日重点评级关注：瑞杰金融：上调Lumexa Imaging Holdings评级至"强力买入"，目标价23美元；BTIG：维持Transocean"买入"评级，目标价从6美元升至10美元
02-10 10:29
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $8 Price Target
D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $8 price target.
02-09 20:31
Why STMicroelectronics Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of STMicroelectronics NV (NYSE:STM) rose sharply in pre-market trading a...
02-09 18:56
美股大行评级 | 希捷科技、德州仪器、HCA控股、通用汽车、波音、UPS等或多家机构上调目标价；布朗保险、康沃系统、Qorvo、联合健康等遭多家机构下调目标价
今日重点评级关注：Piper Sandler：维持Praxis Precision Medicine"超配"评级，目标价从450美元升至1200美元；Tigress Financial：维持Main International ETF"买入"评级，目标价从52美元升至66美元
01-29 11:06
D. Boral Capital Maintains Buy on Estrella Immunopharma, Lowers Price Target to $8
D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and lowers the price target from $16 to $8.
01-28 20:04
Estrella Immunopharma Offers Up To 2,541,206 Shares For Resale By The Selling Stockholders
ESTRELLA IMMUNOPHARMA, INC.Up to 2,541,206 Shares of Common StockThis prospectus relates to the offer and resale from time to time by the selling stockholders named in this prospectus (the "Selling Stockholders") of
2025-12-23 00:00
Estrella Immunopharma Recommended By Independent Data Safety Monitoring Board To Advance STARLIGHT-1 Study To Phase II After Review Of Safety Data
Estrella Immunopharma, Inc. (NASDAQ: ESLA) ("Estrella" or the "Company"), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® T-cell therapies to treat cancer and autoimmune
2025-12-04 21:04
美股大行评级 | 高盛上调英伟达目标价升至240美元； Loop Capital上调英伟达目标价升至350美元！
今日重点评级关注：花旗：维持Caribou Biosciences"买入"评级，目标价从5美元升至8美元；HC Wainwright & Co.：上调MoonLake Immunotherapeutics - Class A Ordinary Shares评级至"买入"，目标价30美元
2025-11-04 10:31
D. Boral Capital Maintains Buy on Estrella Immunopharma, Maintains $16 Price Target
D. Boral Capital analyst Jason Kolbert maintains Estrella Immunopharma (NASDAQ:ESLA) with a Buy and maintains $16 price target.
2025-11-04 00:23
